Free Trial

TELA Bio Q2 2023 Earnings Report

TELA Bio logo
$2.83 -0.01 (-0.35%)
As of 04:00 PM Eastern

TELA Bio Earnings Headlines

These Space Stocks CRUSH AI
Everyone is focusing on AI stocks... Yet little-known "space stocks" are rocketing to record highs with gains of 588% - 3,710%! One new space stock that I call "the next SpaceX" is preparing to IPO on the NASDAQ. Right now, you can grab Pre-IPO shares for less than $4.00. And my estimates suggest the valuation could soar 457% with the IPO. Get urgent details inside this free report...
See More TELA Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TELA Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TELA Bio and other key companies, straight to your email.

About TELA Bio

TELA Bio (NASDAQ:TELA), a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

View TELA Bio Profile

More Earnings Resources from MarketBeat